Kratko priopćenje
Recombinant Factor VIIa in Massive Haemoptysis Associated with Chronic Necrotising Aspergillosis
Miroslav Samardžija
Dražena Srdić
Gzim Redžepi
Sanja Pleština
Ivica Mažuranić
Marko Jakopović
Neven Miculinić
Sažetak
The successful use of recombinant activated factor VII (rFVIIa), in treating massive, life-threatening haemoptysis in a
55-year-old male patient with chronic necrotising aspergillosis, is reported. Patient diagnosed with chronic necrotising
aspergillosis three months ago was admitted to our department with massive haemoptysis. Patient was treated as outpatient
with itraconazole. One day post-admission, two doses of rFVIIa (30 mg·kg–1) were administered and the haemoptysis
was successfully resolved. Two further doses of rFVIIa (30 mg·kg–1) were given the following day, and after that
there were no more recurrences of pulmonary haemorrhage. No thromboembolic or other adverse events were observed
following rFVIIa therapy. Our findings suggest that use of rFVIIa may represent a safe and effective treatment choice for
patients with haemoptysis due to aspergillosis.
Ključne riječi
haemoptysis; recombinant activated factor VII; pulmonary aspergillosis
Hrčak ID:
27019
URI
Datum izdavanja:
2.9.2008.
Posjeta: 891 *